In:
Blood, American Society of Hematology, Vol. 135, No. 22 ( 2020-05-28), p. 1994-1997
Kurzfassung:
Two articles this week focus on Erdheim-Chester disease (ECD), a rare histiocytosis that mainly affects adults. Clonal somatic mutations primarily involving proteins in the BRAF and MPAK pathways have established ECD as a myeloid neoplasm, with targeted therapies now available for patients. In the first paper, an international panel presents new consensus recommendations for evaluation and treatment of ECD. In the second paper, Pegoraro and colleagues present long-term outcomes of patients with ECD treated with sirolimus, with responses in patients both with and without BRAF mutations.
Materialart:
Online-Ressource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood.2019004478
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2020
ZDB Id:
1468538-3
ZDB Id:
80069-7
